Literature DB >> 23266358

A mouse model of in vivo chemical inhibition of retinal calcium-independent phospholipase A2 (iPLA2).

Sarah Saab-Aoudé1, Alain M Bron, Catherine P Creuzot-Garcher, Lionel Bretillon, Niyazi Acar.   

Abstract

Numerous studies have reported the implication of calcium-independent phospholipase A2 (iPLA2) in various biological mechanisms. Most of these works have used in vitro models and only a few have been carried out in vivo on iPLA2(-/-) mice. The functions of iPLA2 have been investigated in vivo in the heart, brain, pancreatic islets, and liver, but not in the retina despite its very high content in phospholipids. Phospholipids in the retina are known to be involved in several various key mechanisms such as visual transduction, inflammation or apoptosis. In order to investigate the implication of iPLA2 in these processes, this work was aimed to build an in vivo model of iPLA2 activity inhibition. After testing the efficacy of different chemical inhibitors of iPLA2, we have validated the use of bromoenol lactone (BEL) in vitro and in vivo for inhibiting the activity of iPLA2. Under in vivo conditions, a dose of 6μg/g of body weight of BEL in mice displayed a 50%-inhibition of retinal iPLA2 activity 8-16h after intraperitoneal administration. Delivering the same dose twice a day to animals was successful in producing a similar inhibition that was stable over one week. In summary, this novel mouse model exhibits a significant inhibition of retinal iPLA2 activity. This model of chemical inhibition of iPLA2 will be useful in future studies focusing on iPLA2 functions in the retina.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23266358     DOI: 10.1016/j.biochi.2012.12.008

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  6 in total

1.  Mechanism-based inhibition of iPLA2β demonstrates a highly reactive cysteine residue (C651) that interacts with the active site: mass spectrometric elucidation of the mechanisms underlying inhibition.

Authors:  Christopher M Jenkins; Jingyue Yang; Richard W Gross
Journal:  Biochemistry       Date:  2013-06-10       Impact factor: 3.162

2.  Definition of a Novel Pathway Centered on Lysophosphatidic Acid To Recruit Monocytes during the Resolution Phase of Tissue Inflammation.

Authors:  Simon McArthur; Thomas Gobbetti; Dennis H M Kusters; Christopher P Reutelingsperger; Roderick J Flower; Mauro Perretti
Journal:  J Immunol       Date:  2015-06-22       Impact factor: 5.422

3.  A mitochondrial pathway for biosynthesis of lipid mediators.

Authors:  Yulia Y Tyurina; Samuel M Poloyac; Vladimir A Tyurin; Alexander A Kapralov; Jianfei Jiang; Tamil Selvan Anthonymuthu; Valentina I Kapralova; Anna S Vikulina; Mi-Yeon Jung; Michael W Epperly; Dariush Mohammadyani; Judith Klein-Seetharaman; Travis C Jackson; Patrick M Kochanek; Bruce R Pitt; Joel S Greenberger; Yury A Vladimirov; Hülya Bayır; Valerian E Kagan
Journal:  Nat Chem       Date:  2014-04-20       Impact factor: 24.427

4.  Modification of erythrocyte membrane phospholipid composition in preterm newborns with retinopathy of prematurity: The omegaROP study.

Authors:  Rémi Karadayi; Charlotte Pallot; Stéphanie Cabaret; Julie Mazzocco; Pierre-Henry Gabrielle; Denis S Semama; Corinne Chantegret; Ninon Ternoy; Delphine Martin; Aurélie Donier; Stéphane Gregoire; Catherine P Creuzot-Garcher; Alain M Bron; Lionel Bretillon; Olivier Berdeaux; Niyazi Acar
Journal:  Front Cell Dev Biol       Date:  2022-09-09

5.  Involvement of plasmalogens in post-natal retinal vascular development.

Authors:  Sarah Saab; Bénédicte Buteau; Laurent Leclère; Alain M Bron; Catherine P Creuzot-Garcher; Lionel Bretillon; Niyazi Acar
Journal:  PLoS One       Date:  2014-06-25       Impact factor: 3.240

6.  Bromoenol Lactone Attenuates Nicotine-Induced Breast Cancer Cell Proliferation and Migration.

Authors:  Lindsay E Calderon; Shu Liu; Nova Arnold; Bethany Breakall; Joseph Rollins; Margaret Ndinguri
Journal:  PLoS One       Date:  2015-11-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.